Document Detail

Peroxisome proliferator-activated receptor delta (PPARdelta), a novel target site for drug discovery in metabolic syndrome.
MedLine Citation:
PMID:  16713711     Owner:  NLM     Status:  MEDLINE    
The development of new treatments for metabolic syndrome is urgent project for decreasing the prevalence of coronary heart disease and diabetes mellitus in the advanced countries. Peroxisome proliferator-activated receptor (PPAR)alpha and gamma agonists have shed light on the treatment of hypertriglyceridemia and type 2 diabetes mellitus, respectively. Among PPARs, analysis of the PPARdelta functions is lagging behind because specific PPARdelta agonists have not been developed. The appearance of new PPARdelta agonists is brightening the prospects for elucidating the physiological role of PPARdelta. PPARdelta is a new target for the treatment of metabolic syndrome. In particular, the fact that fatty acid oxidation and energy dissipation in skeletal muscle and adipose tissue by PPARdelta agonists lead to improved lipid profile, reduced adiposity and insulin sensitivity is a breakthrough. It seems that treatment of PPARdelta agonists operate similarly to the caloric restriction and prolonged exercise. We suggest that the physiological role of PPARdelta may be an indicator for switching from glucose metabolism to fatty acid metabolism. To receive new benefits of PPARdelta agonists against metabolic syndrome by increasing fatty acid consumption in skeletal muscle and adipose tissue, we need to unveil more details on the functions of PPARdelta itself and its agonists in the future.
Sadao Takahashi; Toshiya Tanaka; Tatsuhiko Kodama; Juro Sakai
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2006-03-29
Journal Detail:
Title:  Pharmacological research : the official journal of the Italian Pharmacological Society     Volume:  53     ISSN:  1043-6618     ISO Abbreviation:  Pharmacol. Res.     Publication Date:  2006 Jun 
Date Detail:
Created Date:  2006-05-29     Completed Date:  2006-10-26     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8907422     Medline TA:  Pharmacol Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  501-7     Citation Subset:  IM    
Third Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Fukui 910-0063, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adipocytes / cytology,  metabolism
Atherosclerosis / prevention & control
Cell Differentiation
Drug Design*
Fatty Acids / metabolism
Lipoproteins / metabolism
Metabolic Syndrome X / drug therapy*
Muscle, Skeletal / metabolism
Myocytes, Cardiac / drug effects
PPAR delta / agonists*,  physiology
Reg. No./Substance:
0/Fatty Acids; 0/Lipoproteins; 0/PPAR delta

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A comparison of muscle activity and heart rate response during backward and forward walking on an un...
Next Document:  Determination of peptide and protein ion charge states by Fourier transformation of isotope-resolved...